Document Detail


Choosing medical or surgical terminations of pregnancy in the first trimester: what is the difference?
MedLine Citation:
PMID:  19432614     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Women seeking termination of pregnancy in Auckland, New Zealand can chose between medical and surgical options up to eight weeks gestation. AIMS: To assess demographic differences or changes over time between proportions of women choosing medical or surgical abortions at a single centre and determine whether changing the mifepristone-misoprostol interval from two to one day impacted on outcomes. METHODS: Retrospective audit of two consecutive years (December 2005-November 2006 and December 2006-November 2007) of first-trimester surgical and medical terminations where the mifepristone-misoprostol interval was reduced from two to one day between years. Analysis using descriptive statistics and assessment of probability of observed differences between groups. RESULTS: A total of 1495 terminations were performed in 2005-2006 and 1588 in 2006-2007. No significant difference (P = 0.4) of eligible women choosing medical (21% and 23%) or surgical abortion between years. Ethnicity, age and residency status did not influence choice. Medical termination of pregnancy was more likely in women who were without previous children (P = 0.009), pregnancies (P = 0.02) or terminations (P = 0.04). Medical termination was similarly effective within six hours with either two- or one-day intervals. CONCLUSIONS: Both medical and surgical first-trimester abortions are safe and effective. It is optimal to be able to offer women choice. Reducing the medical interval to one day does not increase adverse outcomes.
Authors:
Felicity Goodyear-Smith; Alison Knowles
Related Documents :
1766444 - Judging social issues: difficulties, inconsistencies, and consistencies.
10457864 - Misoprostol used alone for the termination of early pregnancy. a review of the evidence.
11809024 - Freud's struggle with misogyny: homosexuality and guilt in the dream of irma's injection.
14518484 - Idealists or pragmatists? progressives and separatists among australian medical women, ...
9876704 - Hans frangenheim--culdoscopy vs. laparoscopy, the first book on gynecological endoscopy...
17149984 - Profiling in basketball: physical and physiological characteristics of elite players.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Australian & New Zealand journal of obstetrics & gynaecology     Volume:  49     ISSN:  1479-828X     ISO Abbreviation:  Aust N Z J Obstet Gynaecol     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-05-12     Completed Date:  2009-08-03     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0001027     Medline TA:  Aust N Z J Obstet Gynaecol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  211-5     Citation Subset:  IM    
Affiliation:
Department of General Practice and Primary Health Care, School of Population Health, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. f.goodyear-smith@auckland.ac.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents / administration & dosage
Abortion, Induced / methods*,  psychology*
Adult
Choice Behavior*
Drug Administration Schedule
Drug Therapy, Combination
Female
Gravidity
Humans
Mifepristone / administration & dosage
Misoprostol / administration & dosage
New Zealand
Patient Participation*
Pregnancy
Pregnancy Trimester, First
Retrospective Studies
Vacuum Curettage
Young Adult
Chemical
Reg. No./Substance:
0/Abortifacient Agents; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone
Comments/Corrections
Comment In:
Aust N Z J Obstet Gynaecol. 2009 Oct;49(5):564   [PMID:  19780750 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of three management strategies for patients with atypical squamous cells of undetermined ...
Next Document:  Association of p53 polymorphism with ICSI/IVF failure and recurrent pregnancy loss.